AKBA

Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on developing and commercializing treatments for kidney disease. Headquartered in Cambridge, Massachusetts, Akebia specializes in innovative therapies for patients with chronic kidney disease (CKD), including anemia management.

The company's lead product, Vafseo (vadadustat), is designed to treat anemia due to CKD in both dialysis-dependent and non-dialysis patients.